The intensification of anticancer activity of LFM-A13 by erythropoietin as a possible option for inhibition of breast cancer-Reference-Cited by-同舟云学术

The intensification of anticancer activity of LFM-A13 by erythropoietin as a possible option for inhibition of breast cancer

Published:2020-01-01 Issue:1 Volume:35 Page:1697-1711
ISSN:1475-6366
Container-title:Journal of Enzyme Inhibition and Medicinal Chemistry
language:en
Short-container-title:Journal of Enzyme Inhibition and Medicinal Chemistry

Author:

Rozkiewicz Dariusz¹,Hermanowicz Justyna Magdalena¹²,Tankiewicz-Kwedlo Anna³,Sieklucka Beata¹,Pawlak Krystyna³,Czarnomysy Robert⁴,Bielawski Krzysztof⁴^ORCID,Surazynski Arkadiusz⁵,Kalafut Joanna⁶,Przybyszewska Alicja⁶,Koda Mariusz⁷,Jakubowska Katarzyna⁸,Rivero-Muller Adolfo⁶,Pawlak Dariusz¹

Affiliation:

1. Department of Pharmacodynamics, Medical University of Bialystok, Bialystok, Poland

2. Department of Clinical Pharmacy, Medical University of Bialystok, Bialystok, Poland

3. Department of Monitored Pharmacotherapy, Medical University of Bialystok, Bialystok, Poland

4. Department of Synthesis and Technology of Drugs, Medical University of Bialystok, Bialystok, Poland

5. Department of Medicinal Chemistry, Medical University of Bialystok, Bialystok, Poland

6. Department of Biochemistry and Molecular Biology, Medical University of Lublin, Lublin, Poland

7. Department of General Pathomorphology, Medical University of Bialystok, Bialystok, Poland

8. Department of Pathomorphology, Comprehensive Cancer Center, Bialystok, Poland

Funder

Medical University of Bialystok, Poland.

Publisher

Informa UK Limited

Subject

Drug Discovery,Pharmacology,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/14756366.2020.1818738

Reference41 articles.

1. Erythropoietin Blockade Inhibits the Induction of Tumor Angiogenesis and Progression

2. Erythropoietin regulates tumour growth of human malignancies

3. Erythropoietin drives breast cancer progression by activation of its receptor EPOR

4. Erythropoietin promotes breast tumorigenesis through tumor-initiating cell self-renewal

5. Identification of Cell Type-Specific Differences in Erythropoietin Receptor Signaling in Primary Erythroid and Lung Cancer Cells

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Decoding the tumor microenvironment and molecular mechanism: unraveling cervical cancer subpopulations and prognostic signatures through scRNA-Seq and bulk RNA-seq analyses;Frontiers in Immunology;2024-02-28

2. Bruton’s Tyrosine Kinase Inhibitors (BTKIs): Review of Preclinical Studies and Evaluation of Clinical Trials;Molecules;2023-03-06

3. Recombinant human erythropoietin accelerated the proliferation of non‐small cell lung cancer cell lines and reduced the expression of VEGF, HIF‐1α, and PD‐L1 under a simulated hypoxic environment in vitro;Chronic Diseases and Translational Medicine;2022-03-31

4. Preclinical Toxicity and Safety of MM-129—First-in-Class BTK/PD-L1 Inhibitor as a Potential Candidate against Colon Cancer;Pharmaceutics;2021-08-07